UHPLC Analysis of Intact Infliximab on BIOshell(TM) A400 Protein C4

UHPLC Analysis of Intact Infliximab on BIOshell™ A400 Protein C4

Conditions

column BIOshell A400 Protein C4; 10 cm x 2.1 mm I.D., 3.4 μm particles (66825-U)
column temp. 75 °C
mobile phase [A] 70:25:5 water (0.1% TFA): acetonitrile (0.1% TFA): 1-butanol (0.1% TFA); [B] 50:45:5 water (0.1% TFA): acetonitrile (0.1% TFA): 1-butanol (0.1% TFA)
gradient 0% B to 100% B in 15 min
flow rate 0.2 mL/min
pressure 680 psi (46 Bar)
sample Infliximab, 100 μg/mL, water (0.05% TFA)
injection 5 μL
detector UV, 215 nm

Description

Analysis Note Infliximab (brand name Remicade) is an immunosuppressive biologic drug used to treat rheumatoid arthritis, psoriatic arthritis, Crohn′s disease, and many other diseases by blocking TNF alpha which prevents an autoimmune reaction. It has a molecular weight of ~150 kDa. The BIOshell A400 Protein C4 UHPLC column yielded an efficient peak for this protein in less than five minutes.
Featured Industry Pharmaceutical (small molecule)
Legal Information BIOshell is a trademark of Sigma-Aldrich Co. LLC
suitability application for UHPLC

Materials

     
Related Links